SCHEMBL24125166

SCHEMBL24125166

Cc1ccccc1COc1ccc(CNc2ccc3cncnc3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.50
EGFR P00533 2/20 0.44
MAPT P10636 6/20 0.44
GAA P10253 4/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
TP53 P04637 3/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
HSD17B10 Q99714 2/20 0.43
RAB9A P51151 4/20 0.43
F2 P00734 1/20 0.42
HPGD P15428 1/20 0.42
BLM P54132 1/20 0.40
ATM Q13315 1/20 0.40
IMPDH2 P12268 2/20 0.40
NPC1 O15118 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25920275 0.88 GAA (0.60) NOTUMEGFRMAPTGAAKMT2A
SCHEMBL24124319 0.86 F2 (0.58) NOTUMEGFRMAPTGAAKMT2A
SCHEMBL25920960 0.85 EGFR (0.48) NOTUMEGFRMAPTGAAKMT2A
SCHEMBL24124769 0.85 F2 (0.53) NOTUMEGFRMAPTGAAKMT2A
SCHEMBL24124999 0.83 IMPDH2 (0.50) NOTUMEGFRMAPTGAAKMT2A
SCHEMBL25920273 0.81 PPARA (0.51) EGFRMAPTGAAKMT2AMEN1
SCHEMBL25920276 0.80 PPARA (0.48) NOTUMEGFRMAPTGAAKMT2A
SCHEMBL24124251 0.79 EGFR (0.54) NOTUMEGFRMAPTKMT2AMEN1
SCHEMBL24125162 0.79 MAOB (0.48) EGFRMAPTGAAKMT2AMEN1
SCHEMBL24124191 0.78 NOTUM (0.53) NOTUMEGFRMAPTGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 NOTUM 2800/4885EGFR 1566/4885MAPT 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.